PELI2 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9HAT8 |
---|---|
Clone Names | 100405151 |
Gene ID | 57161 |
---|---|
Other Names | E3 ubiquitin-protein ligase pellino homolog 2, Pellino-2, 632-, PELI2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PELI2 |
---|---|
Function | E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL- 1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates IL1B-induced IRAK1 'Lys-63'-linked polyubiquitination and possibly 'Lys-48'-linked ubiquitination. May be important for LPS- and IL1B-induced MAP3K7-dependent, but not MAP3K3- dependent, NF-kappa-B activation. Can activate the MAP (mitogen activated protein) kinase pathway leading to activation of ELK1. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Scaffold protein which probably links Toll-like receptors (TLRs) to basic cellular processes via its interaction with the complex containing IRAK kinases and TRAF6. Can activate the MAP (mitogen activated protein) kinase pathway leading to activation of ELK1. Not required for NF-kappa-B activation.
References
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Ordureau, A., et al. Biochem. J. 409(1):43-52(2008)Lim, J., et al. Cell 125(4):801-814(2006)Liu, Y., et al. J. Biol. Chem. 279(36):37436-37444(2004)Strelow, A., et al. FEBS Lett. 547 (1-3), 157-161 (2003) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.